↓ Skip to main content

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

Overview of attention for article published in Journal for Immunotherapy of Cancer, July 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#45 of 2,018)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
13 news outlets
twitter
43 tweeters

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
17 Mendeley
Title
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Published in
Journal for Immunotherapy of Cancer, July 2021
DOI 10.1136/jitc-2021-002890
Pubmed ID
Authors

Amanda C Guidon, Leeann B Burton, Bart K Chwalisz, James Hillis, Teilo H Schaller, Anthony A Amato, Allison Betof Warner, Priscilla K Brastianos, Tracey A Cho, Stacey L Clardy, Justine V Cohen, Jorg Dietrich, Michael Dougan, Christopher T Doughty, Divyanshu Dubey, Jeffrey M Gelfand, Jeffrey T Guptill, Douglas B Johnson, Vern C Juel, Robert Kadish, Noah Kolb, Nicole R LeBoeuf, Jenny Linnoila, Andrew L Mammen, Maria Martinez-Lage, Meghan J Mooradian, Jarushka Naidoo, Tomas G Neilan, David A Reardon, Krista M Rubin, Bianca D Santomasso, Ryan J Sullivan, Nancy Wang, Karin Woodman, Leyre Zubiri, William C Louv, Kerry L Reynolds

Twitter Demographics

The data shown below were collected from the profiles of 43 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 4 24%
Other 3 18%
Researcher 2 12%
Student > Postgraduate 2 12%
Professor 1 6%
Other 1 6%
Unknown 4 24%
Readers by discipline Count As %
Unspecified 4 24%
Medicine and Dentistry 3 18%
Pharmacology, Toxicology and Pharmaceutical Science 2 12%
Economics, Econometrics and Finance 1 6%
Biochemistry, Genetics and Molecular Biology 1 6%
Other 2 12%
Unknown 4 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 111. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 August 2021.
All research outputs
#238,344
of 18,810,040 outputs
Outputs from Journal for Immunotherapy of Cancer
#45
of 2,018 outputs
Outputs of similar age
#6,233
of 301,835 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#3
of 125 outputs
Altmetric has tracked 18,810,040 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,018 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 301,835 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 125 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.